- Home
- NUVB vs PCN Comparison
NUVB vs PCN Comparison
Compare NUVB & PCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- PCN
- Stock Information
- Founded
- NUVB 2018
- PCN 2001
- Country
- NUVB United States
- PCN United States
- Employees
- NUVB N/A
- PCN N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- PCN Investment Managers
- Sector
- NUVB Health Care
- PCN Finance
- Exchange
- NUVB Nasdaq
- PCN Nasdaq
- Market Cap
- NUVB 959.2M
- PCN 781.6M
- IPO Year
- NUVB N/A
- PCN N/A
- Fundamental
- Price
- NUVB $2.58
- PCN $13.51
- Analyst Decision
- NUVB Strong Buy
- PCN
- Analyst Count
- NUVB 6
- PCN 0
- Target Price
- NUVB $7.00
- PCN N/A
- AVG Volume (30 Days)
- NUVB 2.8M
- PCN 218.7K
- Earning Date
- NUVB 02-27-2025
- PCN 01-01-0001
- Dividend Yield
- NUVB N/A
- PCN 9.73%
- EPS Growth
- NUVB N/A
- PCN N/A
- EPS
- NUVB N/A
- PCN N/A
- Revenue
- NUVB $2,162,000.00
- PCN N/A
- Revenue This Year
- NUVB N/A
- PCN N/A
- Revenue Next Year
- NUVB $369.72
- PCN N/A
- P/E Ratio
- NUVB N/A
- PCN N/A
- Revenue Growth
- NUVB N/A
- PCN N/A
- 52 Week Low
- NUVB $1.52
- PCN $10.70
- 52 Week High
- NUVB $4.16
- PCN $14.48
- Technical
- Relative Strength Index (RSI)
- NUVB 45.02
- PCN 45.46
- Support Level
- NUVB $2.47
- PCN $13.23
- Resistance Level
- NUVB $2.77
- PCN $13.56
- Average True Range (ATR)
- NUVB 0.23
- PCN 0.12
- MACD
- NUVB -0.04
- PCN 0.02
- Stochastic Oscillator
- NUVB 13.30
- PCN 73.68
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.